alendronate has been researched along with HIV Wasting Syndrome in 2 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
HIV Wasting Syndrome: Involuntary weight loss of greater than 10 percent associated with intermittent or constant fever and chronic diarrhea or fatigue for more than 30 days in the absence of a defined cause other than HIV infection. A constant feature is major muscle wasting with scattered myofiber degeneration. A variety of etiologies, which vary among patients, contributes to this syndrome. (From Harrison's Principles of Internal Medicine, 13th ed, p1611).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Three completed randomised-controlled studies examined the role of alendronate in patients with HIV and osteopenia or osteoporosis." | 4.84 | Interventions for the treatment of decreased bone mineral density associated with HIV infection. ( Lin, D; Rieder, MJ, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Paccou, J | 1 |
| Viget, N | 1 |
| Legrout-Gérot, I | 1 |
| Yazdanpanah, Y | 1 |
| Cortet, B | 1 |
| Lin, D | 1 |
| Rieder, MJ | 1 |
2 reviews available for alendronate and HIV Wasting Syndrome
| Article | Year |
|---|---|
Bone loss in patients with HIV infection.
Topics: Alendronate; Anti-Retroviral Agents; Bone Density; Bone Density Conservation Agents; Bone Resorption | 2009 |
Interventions for the treatment of decreased bone mineral density associated with HIV infection.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium, Diet | 2007 |